Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2021; 13(10): 1235-1244
Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1235
Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?
Jin-Soo Park, Hans Van der Wall, Catherine Kennedy, Gregory L Falk
Jin-Soo Park, Catherine Kennedy, Gregory L Falk, Upper GI Surgery, Concord Repatriation General Hospital, Sydney 2137, NSW, Australia
Jin-Soo Park, Department of Medicine, University of Notre Dame, Sydney 2007, NSW, Australia
Hans Van der Wall, CNI Molecular Imaging, Notre Dame University, Sydney 2114, NSW, Australia
Author contributions: Park JS contributed to manuscript drafting; Van der Wall H contributed to statistical analysis; Park JS and Kennedy C contributed to data collection, manuscript editing; Van der Wall H and Falk GL contributed to study conception, data collection, manuscript drafting, manuscript editing
Institutional review board statement: Data were extracted from a research database with current approval by the Sydney Local Health District Human Research Ethics Committee (reference: LNR/12CRGH/248).
Informed consent statement: Patients had given written informed consent for the study of data under the institutional ethics committee guidelines.
Conflict-of-interest statement: No conflicts of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at Participants gave informed consent for data sharing. No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Jin-Soo Park, BMed, MD, MS, Doctor, Upper GI Surgery, Concord Repatriation General Hospital, Hospital Road, Concord, Sydney 2137, NSW, Australia.
Received: March 22, 2021
Peer-review started: March 22, 2021
First decision: August 15, 2021
Revised: August 23, 2021
Accepted: September 19, 2021
Article in press: September 19, 2021
Published online: October 27, 2021
Core Tip

Core Tip: This study aimed to compare the effect of neoadjuvant chemotherapy to a standardized surgery and lymphadenectomy on survival outcomes in curative oesophagectomy for cancer. Overall and disease-free survival were similar between neoadjuvant chemotherapy (NACT) and surgery only groups. There was improved survival in patients with ≥ 30 nodes harvested compared to those with < 30 nodes. The possibility that improved lymphadenectomy techniques, as opposed to NACT, improves survival outcomes in curative resection of oesophageal adenocarcinoma warrants further investigation.